Skip to content

Study · Non-randomized trial · n = 42 · 2021

5 results

Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism.

Abbara A, Eng PC, Phylactou M, Clarke SA, Mills E, Chia G, Yang L, Izzi-Engbeaya C, Smith N, Jayasena CN, Comninos AN, Anand-Ivell R and 5 more

Show all authors

Rademaker J, Xu C, Quinton R, Pitteloud N, Dhillo WS

Neuroendocrinology23 Nov 2020Cited by 17 (Europe PMC)

PMID33227799 (opens in a new tab)DOI10.1159/000513248 (opens in a new tab)PepBankPUB-33227799
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In men with congenital hypogonadotropic hypogonadism, the maximal LH rise after kisspeptin‑54 was much smaller than in healthy men.

    In plain wordsAfter kisspeptin‑54, men with congenital hypogonadotropic hypogonadism had a much smaller rise in luteinizing hormone than healthy men.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseMaximal LH rise after kisspeptin-54, CHH versus healthy men
    Study

    n = 42

    Comparator
    Healthy eugonadal men
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    6.4 nmol/kg · intravenous bolusAs given in this study (human).

    Measurements

    Maximal LH rise
    12.5 iU/L
    healthy men
    Maximal LH rise
    0.4 iU/L
    men with CHH

    Source sentences

    Summary
    Maximal luteinizing hormone (LH) rise after KP54 was significantly greater in healthy men (12.5 iU/L) than in men with CHH (0.4 iU/L; p < 0.0001).
    1 context sentence
    Summary · context
    Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide.
  2. 02HumanNon-randomized trialOther

    In men with CHH and healthy men, the kisspeptin‑54 test separated the two groups more accurately than the GnRH test (AUROC 1.0 versus 0.88).

    In plain wordsKisspeptin‑54 told men with congenital hypogonadotropic hypogonadism apart from healthy men more accurately than GnRH did.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableAccuracy of kisspeptin-54 test for identifying CHH (AUROC)
    Study

    n = 42

    Comparator
    GnRH
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    6.4 nmol/kg · intravenous bolusAs given in this study (human).

    Measurements

    AUROC
    1 ratio
    kisspeptin-54
    AUROC
    0.88 ratio
    GnRH

    Source sentences

    Summary
    KP54 more accurately differentiated CHH men from healthy men than GnRH (area under receiver operating characteristic curve KP54: 1.0, 95% CI 1.0-1.0; GnRH: 0.88, 95% CI 0.76-0.99).
    1 context sentence
    Summary · context
    Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide.
  3. 03HumanNon-randomized trialActivity measurement

    After kisspeptin‑54, all men with CHH had an LH rise below 2.0 iU/L, whereas all healthy men had a rise above 4.0 iU/L.

    In plain wordsAfter kisspeptin‑54, every man with congenital hypogonadotropic hypogonadism had a small luteinizing hormone rise and every healthy man had a larger one.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableIndividual LH rise cut-offs after kisspeptin-54
    Study

    n = 42

    Comparator
    Healthy eugonadal men
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    6.4 nmol/kg · intravenous bolusAs given in this study (human).

    Measurements

    LH rise
    < 2 iU/L
    men with CHH
    LH rise
    > 4 iU/L
    healthy men

    Source sentences

    Summary
    Indeed, all CHH men had an LH rise 4.0 iU/L.
    1 context sentence
    Summary · context
    Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide.
  4. 04HumanNon-randomized trialActivity measurement

    In men with CHH, anosmic men (Kallmann syndrome) had lower LH rises after kisspeptin‑54 than normosmic men with CHH.

    In plain wordsAfter kisspeptin‑54, men with congenital hypogonadotropic hypogonadism and no sense of smell had lower luteinizing hormone rises than those who could smell.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseLH rise after kisspeptin-54, anosmic versus normosmic men with CHH
    Study

    n: not reported in source

    Comparator
    Normosmic men with CHH
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    6.4 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    Anosmic men with CHH (i.e., Kallmann syndrome) had even lower LH rises after KP54 than did normosmic men with CHH (p = 0.017).
    1 context sentence
    Summary · context
    Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide.
  5. 05HumanNon-randomized trialActivity measurement

    In men with CHH, men with pathogenic or likely pathogenic CHH gene variants had lower LH rises after kisspeptin‑54 than other men with CHH.

    In plain wordsAfter kisspeptin‑54, men with a disease-causing gene variant had lower luteinizing hormone rises than other men with congenital hypogonadotropic hypogonadism.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseLH rise after kisspeptin-54, men with pathogenic CHH gene variants versus other CHH men
    Study

    n: not reported in source

    Comparator
    Other men with CHH
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    6.4 nmol/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    Likewise, men identified to have pathogenic/likely pathogenic variants in CHH genes had even lower LH rises after KP54 than other men with CHH (p = 0.035).
    1 context sentence
    Summary · context
    Men with CHH (n = 21) and healthy eugonadal men (n = 21) received an intravenous bolus of either GnRH (100 μg) or KP54 (6.4 nmol/kg), on 2 occasions, and were monitored for 6 h after administration of each neuropeptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.